Secularism of Cong, Left is euphemism for hating Hindutva, says BJP

Bengaluru, Jul 26: Today, one of the Co-founders of Infosys, SD Shibulal announced that over the last three days (22nd - 24th July) his family members have sold a portion of (representing approximately 0.20 per cent of the paid-up equity share capital) their holding in Infosys Ltd on the stock exchanges.

Proceeds from the partial stake monetization will be utilized for a combination of philanthropic and investment activities.

The sale was executed by Citigroup Global Markets India Private Limited as the Sole Broker.

The Founders, have served Infosys in various capacities, since its inception in 1981 until October 2014. Over the three decades, the Founders have nurtured the company transforming it into one of the professionally run companies in India with a global presence.

This press release is for information purposes only and is not an offer to sell, or a solicitation of an offer to buy, any of the shares described herein. The shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or in any state or other jurisdiction of the United States.

Securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the US Securities Act. 

There has not been and there will not be any public offering of the shares in the United States.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Bengaluru, Jan 3: Prime Minister Narendra Modi on Friday called on young scientists of India to "Innovate, Patent, Produce and Prosper," and said these four steps would lead our country towards faster development. The Prime Minister also stressed on the need to transform the landscape of Indian science, technology and innovation.

"The growth story of India depends on its success in the science and technology sector. There is a need to transform the landscape of Indian science, technology and innovation," Modi said.

Speaking after inaugurating the 107th Session of Indian Science Congress, he said, "My motto for the young scientists in this country is -Innovate, Patent, Produce and Prosper. These four steps will lead our country towards faster development."

"If we innovate we will patent and that in turn will make our production smoother and when we take these products to the people of our country, I'm sure they will prosper," he said, adding that innovation for the people and by the people is the direction of our new India. The Prime Minister also said he was happy to learn that India's ranking has improved in the Global Innovation Index to 52.

"Our programmes have created more technology business incubators in the last five years than in the previous 50 years. I congratulate our scientists for this achievement," he added.